Developer of oral, gut-targeted polymer therapeutics intended for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety advantages, enabling patients to avoid invasive complications of sur...
Developer of oral, gut-targeted polymer therapeutics intended for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety advantages, enabling patients to avoid invasive complications of surgeries and procedures.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.